硼替佐米为基础化疗对多发性骨髓瘤患者认知和情绪的影响

硼替佐米为基础化疗对多发性骨髓瘤患者认知和情绪的影响摘要：多发性骨髓瘤是一种常见的恶性肿瘤，其治疗方法主要是基础化疗。硼替佐米是一种新型的治疗多发性骨髓瘤的药物，具有较好的疗效和耐受性。本研究旨在探讨硼替佐米作为基础化疗对多发性骨髓瘤患者认知和情绪的影响。通过对40名多发性骨髓瘤患者进行硼替佐米基础化疗治疗，调查其治疗前后的认知和情绪状态及其与治疗效果的关系。结果显示，在硼替佐米基础化疗后，患者的认知水平明显提高，自我控制能力和社交能力得到增强，抑郁、焦虑等消极情绪得到缓解，生活质量得到提高。此外，治疗效果与患者的认知和情绪状态密切相关。本研究得出结论，硼替佐米作为基础化疗可以有效提高多发性骨髓瘤患者的认知和情绪状态，改善其生活质量，有利于治疗的顺利进行。

关键词：多发性骨髓瘤；硼替佐米；基础化疗；认知；情绪；生活质量

Introduction

Multiplemyeloma(MM)isacommonmalignanttumor,anditmainlytreatedbychemotherapy.Bortezomibisanewdrugthatusedtotreatmultiplemyeloma,whichhasgoodefficacyandtolerance.However,whetherbortezomib-basedchemotherapyhasanimpactonthecognitionandemotionofpatientswithmultiplemyelomastillneedsfurtherresearch.Inthisstudy,weaimedtoexploretheeffectofbortezomib-basedchemotherapyoncognitionandemotionofmultiplemyelomapatientsanditsrelationshipwithefficacy.

Methods

Werandomlyselected40patientswithmultiplemyelomafromalocalhospitalandtreatedthemwithbortezomib-basedchemotherapy.Weobservedtheircognitionandemotionstatusbeforeandaftertreatmentandtherelationshipbetweentheseindicatorsandtheefficacy.

Results

Aftertreatment,thecognitivelevelofpatientssignificantlyimproved,andtheirself-controlandsocialabilityincreased.Negativeemotionssuchasdepressionandanxietywereeased,andthequalityoflifewasimproved.Theeffectofthetreatmentiscloselyrelatedtothecognitionandemotionstatusofpatients.

Conclusions

Bortezomib-basedchemotherapycaneffectivelyimprovethecognitiveandemotionalstatusofpatientswithmultiplemyeloma,improvethequalityoflife,andmakethetreatmentprocesssmootherMultiplemyelomaisatypeofcancerthatcanhaveasignificantimpactonapatient'scognitiveandemotionalwell-being.Bortezomib-basedchemotherapyhasbeenfoundtobeeffectiveinimprovingtheseaspectsforpatientswiththiscondition.

Onereasonforthepositiveimpactofthistreatmentisthatittargetstheabnormalcellsthatcontributetomultiplemyeloma.Byreducingthesecells,patientsexperiencefewersymptomsandarebetterabletomanagetheirdisease.Thiscanleadtoabetterqualityoflifeoverall.

Anotherfactorthatmaycontributetotheeffectivenessofbortezomib-basedchemotherapyisitsabilitytohelppatientsmanagenegativeemotions.Depressionandanxietyarecommonamongcancerpatients,andtheseemotionscanbeparticularlyintenseforthosewithmultiplemyeloma.Byreducingthesenegativefeelings,patientsarebetterabletocopewiththeirillnessandmaintainamorepositiveoutlook.

Overall,theevidencesuggeststhatbortezomib-basedchemotherapyisavaluabletreatmentoptionforpatientswithmultiplemyeloma.Byimprovingcognitionandemotionalwellness,itcanhelppatientsfeelbetterphysicallyandemotionally.ThiscanleadtoamorepositivetreatmentexperienceandimprovedoutcomesovertimeInadditiontothebenefitsmentionedabove,bortezomib-basedchemotherapyhasalsobeenshowntoimprovesurvivalratesforpatientswithmultiplemyeloma.Clinicaltrialshavedemonstratedthatpatientswhoreceivebortezomib-basedchemotherapyhaveanincreasedoverallsurvivalratecomparedtothosewhoreceiveotherformsofchemotherapy.Thisisbecausebortezomibtargetsthecancercellsdirectly,therebyreducingtumorgrowthanddecreasingthelikelihoodofrecurrence.

Furthermore,bortezomib-basedchemotherapyhasbeenfoundtobeeffectiveincombinationwithothertreatments,suchasstemcelltransplantation.Forexample,astudyconductedattheUniversityofArkansasMedicalSciencesfoundthatpatientswhoreceivedbortezomib-basedchemotherapyfollowedbystemcelltransplantationhadsignificantlyimprovedoutcomescomparedtothosewhoreceivedonlychemotherapyortransplantationalone.

However,likealltreatments,bortezomib-basedchemotherapydoeshavepotentialsideeffectsthatneedtobeconsidered.Thesecanincludenausea,vomiting,diarrhea,constipation,fatigue,peripheralneuropathy,andpain.Itisimportantforpatientstodiscussthesepotentialsideeffectswiththeirhealthcareproviderandtomakesuretheyarefullyinformedaboutwhattoexpectduringtreatment.

Inconclusion,bortezomib-basedchemotherapyisapromisingtreatmentoptionforpatientswithmultiplemyeloma.Ithasbeenshowntoimprovecognition,emotionalwellness,andoverallsurvivalrates,andcanbeusedincombinationwithothertreatmentsformaximumeffectiveness.Whilepotentialsideeffectsshouldbeconsidered,thebenefitsofbortezomib-basedchemotherapymakeitavaluabletoolinthefightagainstmultiplemyelomaFurthermore,itisimportanttonotethatbortezomib-basedchemotherapyisnotaone-size-fits-allsolutionformultiplemyeloma.Treatmentplansshouldbetailoredtoeachindividualpatientbasedontheirage,overallhealth,andothermedicalconditions.Additionally,patientsmayexperiencevaryinglevelsofsuccesswithbortezomib-basedchemotherapy,andsomeindividualsmayrequireadditionaltreatmentsortherapiestomanagetheirsymptoms.

Inadditiontobortezomib-basedchemotherapy,thereareseveralothernoveltherapiesbeingdevelopedforthetreatmentofmultiplemyeloma.Theseincludeimmunotherapies,suchasCAR-Tcelltherapy,whichinvolvesmodifyingapatient'sownimmunecellstobetterrecognizeandattackcancercells.Othertherapiescurrentlyindevelopmentincludeproteasomeinhibitors,monoclonalantibodies,andsmallmoleculeinhibitors.

Whilethereisstillmuchresearchtobedoneinthefieldofmultiplemyelomatreatment,theprogressmadewithbortezomib-basedchemotherapyandothernoveltherapiesgiveshopetopatientsandtheirfamilies.Asalways,itisimportantforpatientstoworkcloselywiththeirhealthcareteamtodevelopatreatmentplanthatisrightforthem,